Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY: EBS )

5.510 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC)... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Emergent Biosolutions Stock Is Surging After The Close
Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher in Monday's after-hours session after the company was awarded a 10-year contract for 
Via Benzinga
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Why Emergent BioSolutions Stock Dived by 9% Today
Investors didn't greet news of the CEO's departure warmly. 
Via The Motley Fool
Is Emergent BioSolutions Stock a Buy Now?
The deluge of bad news seems to be over, and a recovery could be in the works. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Down 75%, Can Emergent BioSolutions Turn Things Around?
Has the stock finally bottomed out? 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About Emergent BioSolutions
Via Benzinga
Recap: Emergent BioSolutions Q1 Earnings
Via Benzinga
Potential Delay In iPhone 15 Debut Could Impact Apple's Margins, Meta's Threads App Faces User Exodus, Microsoft CEO Satya Nadella's Earnings Exceed $1B: Today's Top Stories
New York Times 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Emergent BioSolutions Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Gainers BioNexus Gene Lab Corp (NASDAQ: BGLC) shares surged 50.1% to $7.31 in pre-market trading. BioNexus Gene Lab reported pricing of $5 million public offering and uplisting to the Nasdaq Capital... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Emergent BioSolutions' Two-Dose Anthrax Vaccine Secures FDA Nod; Shares Jump
The FDA approved Emergent BioSolutions Inc's (NYSE: EBS) anthrax vaccine for adults  
Via Benzinga
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
Emergent BioSolutions Announces CEO Transition
From Emergent BioSolutions
Via GlobeNewswire
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Both of these stocks have plummeted more than 50% over the past year. 
Via The Motley Fool
Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data
Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in  
Via Benzinga
Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment
The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. 
Via Benzinga
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Investors approved, if not enthusiastically, their company's latest asset sale. 
Via The Motley Fool
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
Emergent BioSolutions (EBS) Q1 2023 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent Plans $50 Price Point For Narcan OTC Version For Opioid Overdose Reversal
Emergent BioSolutions Inc (NYSE: EBS) looks to price its over-the-counter (OTC) version of its opioid overdose reversal Narcan at around $50 per carton of two 4 mg doses. 
Via Benzinga
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.